齐齐哈尔医学院学报
齊齊哈爾醫學院學報
제제합이의학원학보
JOURNAL OF QIQIHAR MEDICAL COLLEGE
2014年
16期
2397-2399
,共3页
依折麦布%血脂康%联合治疗%高胆固醇血症
依摺麥佈%血脂康%聯閤治療%高膽固醇血癥
의절맥포%혈지강%연합치료%고담고순혈증
Ezetimibe%Xuezhikang%Combination treatment%Hypercholesterolemia
目的:观察依折麦布联合血脂康与血脂康单独治疗高胆固醇血症患者的调脂疗效。方法40例高胆固醇血症患者随机分入联合治疗组(简称“联合组”,n=20)与血脂康单独治疗组(简称“血脂康组”,n=20),分别在冠心病二级预防或/和降糖治疗基础上给予依折麦布(10 mg,1次/日)与血脂康(600 mg,2次/日)、或单独血脂康(600 mg,2次/日)治疗。在第6周观察治疗后禁食12小时空腹血脂水平。结果与各组基础血脂水平相比,6周后两组的空腹血清总胆固醇( TC)、甘油三酯( TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)水平均显著降低(P<0.05)。联合组治疗6周后的空腹血清TC、LDL-C水平均显著低于血脂康组( P<0.05)。结论依折麦布与的联合治疗高胆固醇血症患者比单用血脂康具有更强的调脂疗效。
目的:觀察依摺麥佈聯閤血脂康與血脂康單獨治療高膽固醇血癥患者的調脂療效。方法40例高膽固醇血癥患者隨機分入聯閤治療組(簡稱“聯閤組”,n=20)與血脂康單獨治療組(簡稱“血脂康組”,n=20),分彆在冠心病二級預防或/和降糖治療基礎上給予依摺麥佈(10 mg,1次/日)與血脂康(600 mg,2次/日)、或單獨血脂康(600 mg,2次/日)治療。在第6週觀察治療後禁食12小時空腹血脂水平。結果與各組基礎血脂水平相比,6週後兩組的空腹血清總膽固醇( TC)、甘油三酯( TG)、低密度脂蛋白膽固醇(LDL-C)和高密度脂蛋白膽固醇(HDL-C)水平均顯著降低(P<0.05)。聯閤組治療6週後的空腹血清TC、LDL-C水平均顯著低于血脂康組( P<0.05)。結論依摺麥佈與的聯閤治療高膽固醇血癥患者比單用血脂康具有更彊的調脂療效。
목적:관찰의절맥포연합혈지강여혈지강단독치료고담고순혈증환자적조지료효。방법40례고담고순혈증환자수궤분입연합치료조(간칭“연합조”,n=20)여혈지강단독치료조(간칭“혈지강조”,n=20),분별재관심병이급예방혹/화강당치료기출상급여의절맥포(10 mg,1차/일)여혈지강(600 mg,2차/일)、혹단독혈지강(600 mg,2차/일)치료。재제6주관찰치료후금식12소시공복혈지수평。결과여각조기출혈지수평상비,6주후량조적공복혈청총담고순( TC)、감유삼지( TG)、저밀도지단백담고순(LDL-C)화고밀도지단백담고순(HDL-C)수평균현저강저(P<0.05)。연합조치료6주후적공복혈청TC、LDL-C수평균현저저우혈지강조( P<0.05)。결론의절맥포여적연합치료고담고순혈증환자비단용혈지강구유경강적조지료효。
Objective The effect of ezetimibe and Xuezhikang combination treatment on fasting serum lipids level was investigated in patients with hypercholesterolemia .Methods Forty hypercholesterolemic patients were randomly divided into two groups to accept Xuezhikang ( Xuezhikang group ) 1200 mg/day ( 600 mg twice daily) or Xuezhikang and ezetimibe 10 mg/day ( combination group ) on the base of routine therapy during the whole 6 weeks following-up.Results Both Xuezhikang monotherapy and Xuezhikang combined with ezetimibe significantly reduced fasting serum total cholesterol ( TC ) , low-density lipoprotein cholesterol ( LDL-C ) and triglyceride(TG) levels, and raised fasting high-density lipoprotein cholesterol (HDL-C) in two groups (P <0.05).After 6 weeks, there was no significantly difference in fasting TG and HDL-C levels between Xuezhikang group and combination group (P<0.05).However, the fasting TC and LDL-C levels in combination group were significantly lower than those in Xuezhikang group (P <0.05).Conclusions Combination treatment with ezetimibe and Xuezhikang had relatively better lipid-lowering efficacy than Xuezhikang monotherapy .